164 related articles for article (PubMed ID: 36751113)
1. Dual-targeting therapy against HER3/MET in human colorectal cancers.
Yamasaki A; Miyake R; Hara Y; Okuno H; Imaida T; Okita K; Okazaki S; Akiyama Y; Hirotani K; Endo Y; Masuko K; Masuko T; Tomioka Y
Cancer Med; 2023 Apr; 12(8):9684-9696. PubMed ID: 36751113
[TBL] [Abstract][Full Text] [Related]
2. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.
De Boeck A; Pauwels P; Hensen K; Rummens JL; Westbroek W; Hendrix A; Maynard D; Denys H; Lambein K; Braems G; Gespach C; Bracke M; De Wever O
Gut; 2013 Apr; 62(4):550-60. PubMed ID: 22535374
[TBL] [Abstract][Full Text] [Related]
4. MiR-346-5p promotes colorectal cancer cell proliferation in vitro and in vivo by targeting FBXL2 and activating the β-catenin signaling pathway.
Pan S; Wu W; Ren F; Li L; Li Y; Li W; Wang A; Liu D; Dong Y
Life Sci; 2020 Mar; 244():117300. PubMed ID: 31953162
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
6. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
[TBL] [Abstract][Full Text] [Related]
7. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.
Wang D; Hu G; Du Y; Zhang C; Lu Q; Lv N; Luo S
J Exp Clin Cancer Res; 2017 Feb; 36(1):23. PubMed ID: 28148279
[TBL] [Abstract][Full Text] [Related]
8. Involvement of Met receptor pathway in aggressive behavior of colorectal cancer cells induced by parathyroid hormone-related peptide.
Novoa Díaz MB; Carriere P; Gigola G; Zwenger AO; Calvo N; Gentili C
World J Gastroenterol; 2022 Jul; 28(26):3177-3200. PubMed ID: 36051345
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.
Uddin S; Ahmed M; Hussain A; Abubaker J; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Jehan Z; Bavi P; Siraj AK; Al-Kuraya KS
Am J Pathol; 2011 Feb; 178(2):537-47. PubMed ID: 21281787
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
Uddin S; Hussain AR; Ahmed M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Pathol; 2011 Dec; 179(6):3032-44. PubMed ID: 21978492
[TBL] [Abstract][Full Text] [Related]
11. TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1.
Zheng S; Zhou C; Wang Y; Li H; Sun Y; Shen Z
J Exp Clin Cancer Res; 2020 Jan; 39(1):23. PubMed ID: 31992359
[TBL] [Abstract][Full Text] [Related]
12. Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation.
Yang K; Jiang L; Hu Y; Yu J; Chen H; Yao Y; Zhu X
J Exp Clin Cancer Res; 2015 May; 34(1):40. PubMed ID: 25935853
[TBL] [Abstract][Full Text] [Related]
13. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
14. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
[TBL] [Abstract][Full Text] [Related]
17. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
18. Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression.
Zhang Y; Li KF
Biomed Pharmacother; 2019 Dec; 120():109127. PubMed ID: 31629952
[TBL] [Abstract][Full Text] [Related]
19. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
20. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
